Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Moritz Sparn"'
Publikováno v:
BMC Medical Education, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Surgical training curricula have changed little over the past decades. Current advances in surgical techniques, especially in minimally invasive surgery, as well as the rapidly changing socioeconomic environment pose a major chall
Externí odkaz:
https://doaj.org/article/12dd67cf8e3c449eb6e33a539d8d1beb
Autor:
Richard F. Knoop, Moritz Sparn, Jens Waldmann, Lars Plassmeier, Detlef K. Bartsch, Matthias Lauth, Christoph Hudemann, Volker Fendrich
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 6, Pp 463-470 (2014)
BACKGROUND AND AIMS: BACKGROUND AND AIMSGemcitabine is the standard therapy for patients with pancreatic cancer with metastatic disease. Patients with metastatic pancreatic cancer presenting with increased values of C-reactive protein do not respond
Externí odkaz:
https://doaj.org/article/11c675ee518c463ca5ef00c36a778785
Autor:
Volker Fendrich, Matthias Lauth, Richard Knoop, Lars Plassmeier, Jens Waldmann, Detlef K. Bartsch, Moritz Sparn
Publikováno v:
Pancreatology. 13:502-507
Background and aims Pancreatic cancer is among the most dismal of human malignancies. There are no chemopreventive strategies for pancreatic cancer or its precursor lesions, pancreatic intraepithelial neoplasia (PanINs). Recent evidence suggests that
Autor:
Matthias Lauth, Detlef K. Bartsch, Volker Fendrich, Lars Plassmeier, Jens Waldmann, Richard Knoop, Christoph Hudemann, Moritz Sparn
Publikováno v:
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 6, Pp 463-470 (2014)
Neoplasia: An International Journal for Oncology Research, Vol 16, Iss 6, Pp 463-470 (2014)
BACKGROUND AND AIMS: BACKGROUND AND AIMSGemcitabine is the standard therapy for patients with pancreatic cancer with metastatic disease. Patients with metastatic pancreatic cancer presenting with increased values of C-reactive protein do not respond